Cognitive impairment

Cognitive impairment is a reduction in working memory, attention, reasoning, or verbal fluency induced by a psychoactive substance.

As a drug effect it is acute and dose-proportional, easing as the substance wears off; this sets it apart from clinical impairment such as dementia or acquired brain injury. It ranges from mild slowing and forgetfulness to a near-total inability to retain information or follow a thought to completion.

It is among the most commonly reported adverse effects across psychoactive substances. It is most commonly induced at moderate to high doses under dissociatives such as ketamine and nitrous oxide, and under depressants such as alcohol and GBL; it also appears at high doses under stimulants such as MDMA, cocaine, and methamphetamine, and under psychedelics such as LSD and psilocybin mushrooms when the dose outpaces a person's ability to orient.

Cognitive impairment is felt as a loosening of mental grip: thoughts that begin but fail to land, words that hover just out of reach, and recent information that slips away before it can be used.

It commonly comes with slowed reaction time, a sense of dense mental fog, and difficulty tracking conversation or narrative. Attending to it often worsens it — the effort to recall something makes recall harder. At higher doses, particularly under dissociatives, it can progress to a near-complete suspension of ordinary cognition.

Cognitive impairment arises through different pathways depending on the drug class:

• Dissociatives — block NMDA receptors, disrupting the glutamate signaling that underlies working memory and executive function.
• Depressants — enhance inhibitory transmission broadly, slowing information processing and impairing the encoding of new memories.
• Stimulants — at high doses or with prolonged use, exhaust monoamine reserves; the resulting depletion degrades focus, reasoning, and recall.
• Psychedelics — act on 5-HT2A receptors, disrupting sequential and logical thought and making it difficult to sustain a line of reasoning.

How much each pathway contributes in a given case is not fully understood.

Who experiences it, and how strongly, varies widely. Higher doses raise both the likelihood and severity across all classes. Fatigue, sleep deprivation, and prior depressant use amplify it — especially under dissociatives and depressants — as do stress and distraction at the time of ingestion.

People with lower baseline cognitive reserve tend to notice it more acutely. Expecting to be impaired can reinforce it by increasing self-monitoring. A rested state, familiar environment, and conservative dose all reduce its intensity.